Acelabio (US)
Acelabio (US) is recorded as a service provider in 22 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 22 trials · Latest update first
C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)
Sponsor Celldex Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease
Sponsor Prometheus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
An Open Label Single-Arm Phase 3 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Vedolizumab Intravenous in the Treatment of Pediatric Subjects with Active Chronic Pouchitis
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Sponsor Spyre Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
C5041012 (APD334-303) - An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Sponsor Arena Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis
Sponsor Odyssey Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
I7P-MC-DSAG - An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease (VECTORS)
Sponsor Alimentiv Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease
Sponsor Agomab Spain S.L.U.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active Ulcerative Colitis
Sponsor Prometheus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis
Sponsor Mage Biologics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP 104GI in Adults with Eosinophilic Esophagitis (RESOLVE)
Sponsor Eupraxia Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
C5041006 (APD334 202 or APD334-202EU): A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
Sponsor Arena Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
I6T-MC-AMBZ - A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I6T-MC-AMBA - A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target
Sponsor Alimentiv Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
Sponsor Morphic Therapeutic Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Acelabio (US)?
The 2026-10-09 snapshot links Acelabio (US) to 22 distinct CTIS trials. Recorded services include Laboratory services, Histopathology, Embedding, processing, cutting and digitalization of samples, Endoscopy imaging and biopsy histopathology analysis, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Acelabio (US)?
The most frequently recorded therapeutic areas are Gastroenterology, Immunology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Acelabio (US) conducted?
The linked trials record locations in 23 countries, including Poland, Italy, France, Germany, Belgium. These are trial locations, not confirmed office locations or countries where Acelabio (US) delivered services.
What can this page tell me about Acelabio (US)'s trial experience?
Browse 22 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Acelabio (US). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Acelabio (US) Inc.